Myosenia Gravis and the Rhinomax Trial

The existing evidence before the rhinomax trial was retuximab might be an option that could be used quite early with a subform of myosenia characterized by antibodies to the musculoprotein. There has been rather few studies with new onset myosetinia. But coming from the field on multiple sclerosis where we definitely, since some years, want to hit a bit harder initially, there are a lot of theoretical reasons why it might be good to abrogate or dampen inflammation early in this disease.